A second-generation hexapeptide GHRP with superior GH-releasing potency compared to GHRP-6 — used in research and as a clinical diagnostic tool for assessing growth hormone secretory capacity.
GHRP-2 (Growth Hormone Releasing Peptide-2) is a second-generation synthetic hexapeptide GH secretagogue that builds on the discoveries made with GHRP-6. Developed in the late 1980s and studied through the 1990s, GHRP-2 was engineered to achieve stronger GH-releasing potency than GHRP-6 through strategic D-amino acid substitutions that improve receptor binding affinity and resistance to enzymatic degradation.
In Japan, GHRP-2 (as Pralmorelin, brand name GRF) received pharmaceutical approval as a diagnostic agent for assessing growth hormone deficiency in adults — making it one of the few GHRPs with actual pharmaceutical regulatory approval history. This clinical background gives GHRP-2 an unusually well-characterized safety and pharmacokinetic profile compared to most research peptides.
Like GHRP-6, GHRP-2 activates the ghrelin receptor and produces cortisol and prolactin elevations as off-target effects, though the degree of appetite stimulation is generally reported to be less pronounced than with GHRP-6. Its strong GH-stimulating potency and clinical approval history make it a reference compound for GH secretagogue research.
GHRP-2 binds to GHS-R1a (the ghrelin receptor) with higher affinity than GHRP-6, triggering stronger GH secretion from pituitary somatotrophs. The D-amino acid modifications at specific positions in the hexapeptide chain — particularly D-Ala at position 2 — confer resistance to aminopeptidase enzymes that would rapidly degrade a standard L-amino acid peptide, extending the peptide's duration of action.
The pharmacological result is a shorter, larger GH pulse compared to GHRP-6, reflecting the higher receptor binding affinity and enzyme resistance. Cortisol and prolactin elevations occur through the same ghrelin receptor activation in the hypothalamus and pituitary, though the cortisol elevation may be somewhat less pronounced than with GHRP-6 in some models — a difference researchers have studied to understand ghrelin receptor pharmacology in detail.
If GHRP-6 is a key that opens the GH room but also rattles every other door on the floor, GHRP-2 is a slightly better-cut version of that same key — it opens the GH room faster and more reliably (higher potency), still rattles some of the same doors (cortisol, prolactin), but the key is made of harder metal so it stays sharp longer (enzyme resistance). The building layout (receptor biology) is identical — GHRP-2 is just a better-engineered version of the same key.
Investigación Renuncia de responsabilidad: Lo siguiente refleja investigación clínica y preclínica publicada y no es consejo médico. Consulta a un profesional de la salud licenciado antes de tomar decisiones de salud.
GHRP-2 (Pralmorelin) received regulatory approval in Japan as a diagnostic test for GH deficiency, giving it a documented human clinical dosing profile from GH stimulation test research.
Referencias Clave: Bowers CY et al. (1997). GHRP-2 pharmacology. Endocrine. · Hartman ML et al. (1996). GHRP-2 GH stimulation. J Clin Endocrinol Metab. · Arvat E et al. (1997). GHRP-2 vs GHRP-6. J Endocrinol Invest.
Pralmorelin (GHRP-2) received pharmaceutical approval in Japan as a diagnostic tool for GH deficiency — a notable regulatory milestone for a GHRP. This required clinical trial data demonstrating its ability to reliably stimulate GH release as a pituitary function test.
The D-amino acid (specifically D-Ala) modification in GHRP-2 is a classic peptide chemistry trick. Natural amino acids are "L" configuration. Switching a single amino acid to its "D" mirror image can dramatically increase a peptide's resistance to the proteolytic enzymes (proteases) that would otherwise degrade it in minutes.
GHRP-2 and GHRP-6 are often compared side-by-side in research models specifically to understand how structural modifications to the same basic hexapeptide scaffold change receptor binding and downstream signaling — a classic approach to structure-activity relationship analysis.
Every batch of GHRP-2 with full Certificate of Analysis documentation. Third-party HPLC verification, mass spectrometry confirmation, and sterility testing results are included with each batch.